Immunity Focused Biotherapeutic Developer with a Hybrid of Services and Technology for a Wide Range of Applications: ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA)

Novel Antibody Discovery & Development Targeting a Broad Range of Diseases.

Recipient of Research Grant Funding for Patented HYFT based Methodology.

AI Discovery Platform for Integrated Protein Structure & Function Analysis.

Synergistic Antibody Cocktail, Potently Prevents In Vitro Infection of Cells by the Dominant Omicron Sublineage BA.2, in Addition to All Other Variants of Concern.

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) is a biotherapeutic, innovation-powered company that supports its business partners in their quest to discover and develop novel antibodies against a broad range of target classes and diseases. IPA offers a hybrid of services and programs with advanced platforms and technologies — dynamic scientists and business advisors — to optimize antibody discovery and development, against rare and/or challenging epitopes. IPA operates in Victoria, BC, Canada, Utrecht and Oss, the Netherlands, Cambridge, MA, San Francisco, CA and Fargo, ND.  With over 25 years of experience in the custom antibody business, IPA provides high customer satisfaction and retention through a customized professional approach.

IPA’s Subsidiary BioStrand Secures Second VLAIO Research Grant

On May 9th IPA announced that its subsidiary Biostrand, a Belgian end-to-end multi-omics analysis platform provider, has received a EUR460,000 round of grant funding from VLAIO (Flanders Innovation & Entrepreneurship), the research fund of the Flemish regional government in Belgium. Conditionally awarded in January this year, BioStrand recently satisfied the remaining criteria for the award, which follows an original grant from VLAIO of EUR235,000 in 2020. 

Commenting on the latest grant, Dr. Ingrid Brands, General Manager and co-founder of BioStrand, stated, “Thus far, our patented HYFT based methodology has been applied predominantly to streamline analysis at the syntactic level and combines sequence information with natural language processing. Using the presence, occurrence, and distribution of HYFT patterns in the Biosphere, the focus has been on analysis and integration of sequence-based ‘syntactical’ information. We are now extending the methodology to combine syntactical and structural information and to expand our services portfolio with HYFT based structural and functional modelling functionalities. By linking HYFTs with the 3D structure (and function) of proteins, S_HYFTs, and expanding platform capabilities for AI discovery, we will be able to support an even wider array of applications, including assay development, biomarker discovery, precision medicine, personalized medicine and computer-aided De Novo drug design.”

The strategic objective driving this HYFT based synthesis of syntactical and structural information is to extend IPA technology to encompass the structure of proteins. A key advantage of this blended approach is the detection of protein sequences with similar structures (and function) but without high sequence similarity (distant homologs). A primary application for this approach will be in protein structure prediction, with a particular first focus on antibodies as well as G protein coupled receptors (GPCRs). This will be extended to cover protein-protein interaction prediction (PPI) at a later stage.

IPA is also working on an AI Discovery platform that will leverage advanced AI techniques to facilitate integrated protein structure and function analysis. Combined with existing R&R and Variant Analyzer modules, natural language analysis capabilities and the HYFT based unified syntactical plus structural methodology, The IPA AI discovery platform will empower researchers to fully analyze their data and gain insights across the entire analysis pipeline, from raw sequencing data to biologically relevant aspects such as diagnostics and drug discovery.

The expansion of the IPA omics platform with these advanced functionalities is crucial to become an ambitious market player and position IPA as a one-stop-shop for multiomics analysis,” said Dr. Brands. “We believe that integrating sequence and 3D structure analysis in combination with natural language processing will revolutionize protein structure and function prediction and boost developments in biotechnology and precision medicine. Providing a powerful, integrated, and user-friendly data analysis platform for life sciences researchers is our contribution to ramping up the effectiveness of R&D cycles and enabling the real-time analysis of actionable patient data that will bring precision medicine to the next level. It also takes us one step further in our mission to create a truly effective omics data analysis solution.”

Advanced PolyTope® TATX-03, a Multi-Antibody Cocktail, Potently Prevents In Vitro Infection of Cells by the Currently Dominant Omicron Sublineage BA.2, in Addition to all Other Variants of Concern

On April 20th IPA announced recent data on its PolyTope® TATX-03 antibody cocktail, which demonstrates strong neutralizing activity toward the Omicron subvariant BA.2. The BA.2 pseudovirus was neutralized with a potency comparable to the previously analyzed Omicron BA.1, demonstrating ongoing and continued consistency of the cocktail to potently neutralize SARS-CoV-2 variants of concern (VOC). This functional outcome was supported by demonstrated binding of each individual antibody constituent to spike-protein trimer BA.2, data which is also highly comparable with the binding observed against BA.1.

Various sublineages were identified relatively soon after the SARS-CoV-2 Omicron variant was designated as a VOC. Of the sublineages classified, BA.2 and BA.3 have higher transmission potential than, for example, BA.1. Given the global prevalence and exceptional transmissibility of BA.2, as well as the reality that most antibody therapies authorized by the FDA under Emergency Use Authorization have lost neutralizing potency against the Omicron variants, recent conversations with the Food and Drug Administration led to prioritizing potency screening of IPA’s TATX-03 product toward BA.2. In line with recent in silico modelling predictions at IPA, the in vitro experimental data showed no significant difference in TATX-03 antibody binding to Omicron and the BA.2 sublineage. As anticipated, the IPA rationally designed anti-SARS-CoV-2 cocktail potently prevented cell infection by Omicron sublineage BA.2 pseudovirus particles at similar antibody concentrations compared to BA.1, resulting in complete neutralization of this dominant subvariant.

For more information on ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), visit www.immunoprecise.com. 

DISCLAIMER: This article is purely for informational purposes and is not a recommendation in any way for buying or selling stocks.

Media Contact
Company Name: ImmunoPrecise Antibodies Ltd
Contact Person: Dr. Jennifer Bath
Email: Send Email
Phone: (701) 353-0022
Country: United States
Website: https://www.immunoprecise.com/